China NT Pharma Group Co's revenue for the
six
months ended in Jun. 2024 was HK$33.69 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$40.81 Mil.
China NT Pharma Group Co's Revenue per Share for the
six
months ended in Jun. 2024 was HK$0.13.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.16.
Warning Sign:
China NT Pharma Group Co Ltd revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue per Share Growth Rate was -69.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, China NT Pharma Group Co's highest 3-Year average Revenue per Share Growth Rate was -5.60% per year. The lowest was -69.10% per year. And the median was -29.95% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of China NT Pharma Group Co's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China NT Pharma Group Co's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's Revenue distribution charts can be found below:
* The bar in red indicates where China NT Pharma Group Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$40.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China NT Pharma Group Co (HKSE:01011) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
China NT Pharma Group Co Revenue Related Terms
Thank you for viewing the detailed overview of China NT Pharma Group Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01011 has been successfully added to your 